Biolex Provides Preclinical Results For Direct-acting Thrombolytic BLX-155

Biolex has provided the preclinical results demonstrating that the thrombolytic activity of the company’s full-length recombinant human plasmin (BLX-155), was superior to t-PA in a preclinical study.

BLX-155 is a direct-acting thrombolytic (clot dissolving) agent currently in preclinical development. It is designed to break up blood clots in patients with diseases or conditions such as acute peripheral arterial occlusive disease and deep vein thrombosis, each of which currently lacks an approved thrombolytic agent.

In the study, graft thrombosis was induced in pigs, and the clots were stabilized for 72 hours before treatment. The animals were administered BLX-155, t-PA or a placebo.

The researchers determined that treatment with BLX-155 significantly reduced the release of clot particles into the circulation, in comparison to t-PA.

In addition, overall thrombolytic (clot dissolving) activity was highest after treatment with BLX-155. The researchers concluded that the thrombolytic activity of BLX-155 was superior to t-PA and decreased the risk of emboli.

Jan Turek, president and CEO of Biolex, said: “The development of BLX-155 using the LEX System may allow exploitation of the natural binding, efficacy and safety attributes of native plasmin without the limitations or risks associated with truncated plasmin, plasma-derived plasmin, t-PA, or alfimeprase.”

“In addition to the thrombolytic activity outlined in the research presented today, prior preclinical studies have shown that plasmin has a substantially lower risk of bleeding than t-PA, demonstrating the potential of BLX-155 to provide a safety advantage to patients suffering from blood clots,” he added.